Pharvaris cash reaches €318 million in Q2
Pharvaris (NASDAQ:PHVS) reported second-quarter 2026 results with cash and cash equivalents of €318 million as of June 30, 2026, while advancing clinical programs for its oral bradykinin B2 receptor antagonist deucrictibant.










